Evidence map›Paper›PMID 39063150›Full record

ArticleInternational journal of molecular sciences2024

The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable

Adam Szpechcinski, Joanna Moes-Sosnowska, Paulina Skronska, Urszula Lechowicz, Magdalena Pelc, Malgorzata Szolkowska, Piotr Rudzinski, Emil Wojda, Krystyna Maszkowska-Kopij, Renata Langfort and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Comparing Real-Time PCR and Amplicon-Based NGS for RoutineDiagnostics (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Literature review of advances and challenges inTranslational lung cancer research · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Adam SzpechcinskiDepartment of Genetics and Clinical Immunology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.ORCID 0000-0002-8920-6931
Joanna Moes-SosnowskaDepartment of Genetics and Clinical Immunology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.ORCID 0000-0003-1706-8290
Paulina SkronskaDepartment of Genetics and Clinical Immunology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Urszula LechowiczDepartment of Genetics and Clinical Immunology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Magdalena PelcDepartment of Genetics and Clinical Immunology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Malgorzata SzolkowskaDepartment of Pathology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Piotr RudzinskiClinics of Thoracic Surgery, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Emil WojdaIII Department of Lung Diseases and Oncology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Krystyna Maszkowska-KopijOutpatient Clinic, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Renata LangfortDepartment of Pathology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Tadeusz OrlowskiClinics of Thoracic Surgery, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Pawel SliwinskiII Department of Lung Diseases, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Mateusz PolaczekIII Department of Lung Diseases and Oncology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Joanna Chorostowska-WynimkoDepartment of Genetics and Clinical Immunology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.ORCID 0000-0003-1743-2961

Funding

As the invited paper, a 100% discount of APC (2900 CHF) was offered to this submission. not applicable
6 · The paper itself

Abstract

The emergence of targeted therapies in non-small-cell lung cancer (NSCLC), including inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase, has increased the need for robust companion diagnostic tests. Nowadays, detection of actionable variants in exons 18-21 of the

Indexed as

Carcinoma, Non-Small-Cell LungErbB ReceptorsHigh-Throughput Nucleotide SequencingLung NeoplasmsMutationReal-Time Polymerase Chain ReactionAgedExonsFemaleHumansMaleMiddle AgedSensitivity and SpecificityEGFR protein, humanErbB Receptorsepidermal growth factor receptormolecular diagnosticsmutationsnon-small-cell lung cancertargeted next-generation sequencing

Identifiers

PMID39063150
PMCPMC11277480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.